Your Twin learns with you

30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Peter Giannoudis

Professor

University of Leeds
Country flagUnited Kingdom

Research Interests

Explore related searches

Articles (14)

Bone void-filling cements are one of the preferred materials for managing irregular bone voids, particularly in the geriatric population who undergo many orthopedic surgeries. However, bone marrow mesenchymal stem/stromal cells (BM-MSCs) of older-age donors often exhibit reduced osteogenic capacity. Hence, it is crucial to evaluate candidate bone substitute materials with BM-MSCs from the geriatric population to determine the true osteogenic potential, thus simulating the clinical situation. With this concept, we investigated the osteogenic potential of shell nacre cement (SNC), a bone void-filling cement based on shell nacre powder and ladder-structured siloxane methacrylate, using older donor BM-MSCs (age > 55 years) and young donor BM-MSCs (age < 30 years). Direct and indirect cytotoxicity studies conducted with human BM-MSCs confirmed the non-cytotoxic nature of SNC. The standard colony-forming unit-fibroblast (CFU-F) assay and population doubling (PD) time assays revealed a significant reduction in the proliferation potential (p < 0.0001, p < 0.05) in older donor BM-MSCs compared to young donor BM-MSCs. Correspondingly, older donor BM-MSCs contained higher proportions of senescent, β-galactosidase (SA-β gal)-positive cells (nearly 2-fold, p < 0.001). In contrast, the proliferation capacity of older donor BM-MSCs, measured as the area density of CellTrackerTM green positive cells, was similar to that of young donor BM-MSCs following a 7-day culture on SNC. Furthermore, after 14 days of osteoinduction on SNC, scanning electron microscopy with energy-dispersive spectroscopy (SEM-EDS) showed that the amount of calcium and phosphorus deposited by young and older donor BM-MSCs on SNC was comparable. A similar trend was observed in the expression of the osteogenesis-related genes BMP2, RUNX2, ALP, COL1A1, OMD and SPARC. Overall, the results of this study indicated that SNC would be a promising candidate for managing bone voids in all age groups.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (11)

Alexander Joeris

Head of Clinical Science

-

SWITZERLAND
View details

Fiona Lecky

Clinical Professor of Emergency Medicine

University of Sheffield

UNITED KINGDOM
View details

Eric Kumi-Barimah

Lecturer in Mathematics and Physical Sciences

University of Leeds

UNITED KINGDOM
View details

Elena Jones

Associate Professor

University of Leeds

UNITED KINGDOM
View details

Hemant Pandit

Professor of Elective Orthopaedics and Honorary Consultant

University of Leeds

UNITED KINGDOM
View details

Jehan El-Jawhari

Lecturer

University of Nottingham

UNITED KINGDOM
View details

El Mostafa Raïf

University of Leeds

UNITED KINGDOM
View details

Thuy Do

University of Leeds

UNITED KINGDOM
View details

Neelam Iqbal

KTP Research Associate

University of Bradford

UNITED KINGDOM
View details

Payal Ganguly

University of Leeds

UNITED KINGDOM
View details

Dionysios Papachristou

Professor, Lab Director

University of Patras

GREECE
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.